Novonix updates director holdings with new rights

Novonix Limited filed a Form 6-K that includes an ASX Appendix 3Y detailing a change in director interests for Michael O’Kronley.

Accepted by SEC EDGAR 05/05/2026 - 07:49 AM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Novonix Limited filed a Form 6-K that includes an ASX Appendix 3Y detailing a change in director interests for Michael O’Kronley. The filing records the issue of performance rights to the director following shareholder approval at the AGM held on 15 April 2026.

After this change, Michael O’Kronley holds 9,586,538 performance rights. The notice also confirms that the interests were not traded during a closed period, so no special trading clearance was required.

Key Figures

Director performance rights holding: 9,586,538 performance rights AGM approval date: 15 April 2026 Form type: Form 6-K with Appendix 3Y

3 metrics

Director performance rights holding 9,586,538 performance rights Number of securities held after change for Michael O’Kronley

AGM approval date 15 April 2026 Date of shareholder approval for performance rights issue

Form type Form 6-K with Appendix 3Y Change of Director’s Interest Notice for Novonix Limited

Key Terms

performance rights, Appendix 3Y, listing rule 3.19A.2, closed period

4 terms

performance rights financial

"No. of securities held after change | 9,586,538 performance rights"

Performance rights are conditional awards that give employees or executives the promise of receiving company shares or cash only if the business meets specific targets or survives for a set period. They work like a bonus you only get when certain goals are hit, so they matter to investors because they can increase the number of shares outstanding (dilution), signal management’s incentives and confidence in future results, and affect per-share earnings and valuation.

Appendix 3Y regulatory

"Appendix 3Y Change of Director’s Interest Notice"

listing rule 3.19A.2 regulatory

"We (the entity) give ASX the following information under listing rule 3.19A.2"

closed period regulatory

"Were the interests in the securities or contracts detailed above traded during a + closed period"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Novonix (NVX) report in this Form 6-K filing?

Novonix reports a change in director interests via an ASX Appendix 3Y. Director Michael O’Kronley received performance rights that were approved by shareholders at the 15 April 2026 AGM, updating his total performance rights holding and regulatory disclosure.

How many performance rights does Novonix director Michael O’Kronley hold after the change?

After the change, Michael O’Kronley holds 9,586,538 performance rights. This figure reflects the updated position following the issue of new performance rights that were approved at Novonix’s annual general meeting held on 15 April 2026.

What triggered the change in Michael O’Kronley’s interests at Novonix (NVX)?

The change was triggered by the issue of performance rights to Michael O’Kronley. These performance rights were granted following shareholder approval at Novonix’s annual general meeting on 15 April 2026, and are recorded as a direct interest in the Appendix 3Y notice.

Were Novonix (NVX) director securities traded during a closed period?

The filing states the director’s interests were not traded during a closed period. The Appendix 3Y specifically answers “No” to trading during a closed period, so no prior written clearance for trading was required in connection with this change.

Is Michael O’Kronley’s interest in Novonix securities direct or indirect?

The Appendix 3Y identifies Michael O’Kronley’s interest as direct. This means the recorded 9,586,538 performance rights are held directly in his name, rather than through an intermediary entity or trust, clarifying how the director’s holdings are structured.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE

SECURITIES EXCHANGE ACT OF 1934

For the month of May, 2026

001-41208

(Commission File Number)

NOVONIX LIMITED

(Translation of registrant’s name into English)

Level 38

71 Eagle Street

Brisbane, QLD 4000 Australia

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20‑F or Form 40‑F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

EXHIBIT INDEX

Exhibit No.		Description
Exhibit 99.1		ASX Announcement (Final Director's Interest Notice) dated May 5, 2026

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

NOVONIX LIMITED
By:		/s/ Robert Long
		Robert Long
		Chief Financial Officer

Date: May 5, 2026

Exhibit 99.1

Appendix 3Y

Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity NOVONIX LIMITED

ABN 54 157 690 830

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	MICHAEL O’KRONLEY
Date of last notice	15 December 2025

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest	DIRECT
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.
Date of change	5 May 2026
No. of securities held prior to change	3,723,971 performance rights
Class	Performance rights
Number acquired	5,862,567 performance rights
Number disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Estimated value of performance rights - $1,524,267 (based on closing share price on 4 May 2026).

+ See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 1

Appendix 3Y

Change of Director’s Interest Notice

No. of securities held after change	9,586,538 performance rights
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issue of performance rights following shareholder approval at the AGM held on 15 April 2026.

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest
Name of registered holder (if issued securities)
Date of change
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed
Interest acquired
Interest disposed
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation
Interest after change

+ See chapter 19 for defined terms.

Appendix 3Y Page 2 01/01/2011

Exhibit 99.1

Appendix 3Y

Change of Director’s Interest Notice

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No.
If so, was prior written clearance provided to allow the trade to proceed during this period?
If prior written clearance was provided, on what date was this provided?

+ See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 3

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 EX-99.1 49.3 KB